Vera Therapeutics, Inc. - Class A (VERA)
NASDAQ · Healthcare
As of Jul 20, 2026
Price history
Key statistics
- Market cap
- $3.08B
- P/E ratio
- —
- EPS
- —
- Volume
- 1,008,236
- 52-week high
- —
- 52-week low
- —
- Open
- $38.51
- Day high
- $39.03
- Day low
- $36.71
Financial highlights
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| 2025 | — | -$299.62M | -$4.66 |
| 2024 | — | -$152.15M | -$2.75 |
| 2023 | — | -$95.99M | -$2.25 |
| 2022 | — | -$89.06M | -$3.35 |
| 2021 | — | -$32.61M | -$2.43 |
About Vera Therapeutics, Inc. - Class A
Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to treat immunoglobulin A nephropathy. The company is also advancing MAU868, a monoclonal antibody in Phase 2 clinical development, designed to combat BK viremia infections. Founded in 2016 and based in Brisbane, California, the organization operated as Trucode Gene Repair, Inc. until it rebranded to Vera Therapeutics, Inc. in April 2020.
- CEO
- Gary Barrera
- Employees
- 339
- Country
- US
- IPO date
- May 14, 2021
Similar stocks
Other Healthcare companies
Frequently asked questions
- What is Vera Therapeutics, Inc. - Class A's stock price today?
- VERA is trading at $36.99 as of Jul 20, 2026.
- What is Vera Therapeutics, Inc. - Class A's market cap?
- Vera Therapeutics, Inc. - Class A (VERA) has a market capitalization of $3.08B.
- Does Vera Therapeutics, Inc. - Class A pay a dividend?
- Vera Therapeutics, Inc. - Class A did not pay a dividend in its most recent reported fiscal year.
- What sector is Vera Therapeutics, Inc. - Class A in?
- Vera Therapeutics, Inc. - Class A operates in the Healthcare sector.